Search

Your search keyword '"Botella-Estrada, R"' showing total 160 results
Start Over Author "Botella-Estrada, R" Journal actas dermo-sifiliograficas
160 results on '"Botella-Estrada, R"'

2. [Translated article] Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP)

Author

Couselo-Rodríguez, C., primary, Batalla, A., additional, Carrascosa, J.M., additional, Chicharro, P., additional, González-Quesada, A., additional, de la Cueva, P., additional, Giménez-Arnau, A.M., additional, Gilaberte, Y., additional, Rodríguez-Serna, M., additional, Montero-Vilchez, T., additional, Ruiz-Villaverde, R., additional, Elosua-González, M., additional, Silvestre-Salvador, J.F., additional, Munera-Campos, M., additional, Sánchez-Pérez, J., additional, Carretero, G., additional, Mauleón-Fernández, C., additional, Curto-Barredo, L., additional, Ballano-Ruiz, A., additional, Botella-Estrada, R., additional, Arias-Santiago, S., additional, Navarro-Triviño, F.J., additional, Roustan-Gullón, G., additional, Betlloch, I., additional, del Alcázar, E., additional, Abalde-Pintos, M.T., additional, Suárez-Perez, J., additional, García-Doval, I., additional, Descalzo, M.Á., additional, and Flórez, Á., additional

Published
2024
Full Text
View/download PDF

3. Supervivencia de la ciclosporina en el tratamiento de la dermatitis atópica moderada-grave: Registro Español de Dermatitis Atópica (BIOBADATOP)

Author

Couselo-Rodríguez, C., primary, Batalla, A., additional, Carrascosa, J.M., additional, Chicharro, P., additional, González-Quesada, A., additional, de la Cueva, P., additional, Giménez-Arnau, A.M., additional, Gilaberte, Y., additional, Rodríguez-Serna, M., additional, Montero-Vilchez, T., additional, Ruiz-Villaverde, R., additional, Elosua-González, M., additional, Silvestre-Salvador, J.F., additional, Munera-Campos, M., additional, Sánchez-Pérez, J., additional, Carretero, G., additional, Mauleón-Fernández, C., additional, Curto-Barredo, L., additional, Ballano-Ruiz, A., additional, Botella-Estrada, R., additional, Arias-Santiago, S., additional, Navarro-Triviño, F.J., additional, Roustan-Gullón, G., additional, Betlloch, I., additional, del Alcázar, E., additional, Abalde-Pintos, M.T., additional, Suárez-Perez, J., additional, García-Doval, I., additional, Descalzo, M.Á., additional, and Flórez, Á., additional

Published
2024
Full Text
View/download PDF

4. [Translated article] Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study

Author

Sánchez-Díaz, M., primary, Flórez, Á., additional, Ara-Martín, M., additional, Arias-Santiago, S., additional, Botella-Estrada, R., additional, Cañueto, J., additional, Carretero-Hernández, G., additional, Coto-Segura, P., additional, de Eusebio-Murillo, E., additional, García-Latasa de Araníbar, F.J., additional, García-Patos Briones, V., additional, Gardeazabal García, J., additional, Gómez-Fernández, C., additional, Hernández-Ostiz, S., additional, Izu Belloso, R., additional, López-Ávila, A., additional, Manchado López, P., additional, Martín-Santiago, A., additional, Martinez de Espronceda Ezquerro, I., additional, Mateu-Puchades, A., additional, Mercader-García, P., additional, Notario Rosa, J., additional, Palacio Aller, L., additional, Pérez-Hortet, C., additional, Quintana-Castanedo, L., additional, Rivera, R., additional, Rocamora Duran, V., additional, Rodríguez-Nevado, I.M., additional, Ruiz-Villaverde, R., additional, Suárez, J., additional, Trasobares-Marugán, L., additional, Vizán-de Uña, C., additional, Yanguas, I., additional, Zulaica-Garate, A., additional, García-Doval, I., additional, Descalzo, M.Á., additional, Grau-Pérez, M., additional, and Carrascosa-Carrillo, J.M., additional

Published
2024
Full Text
View/download PDF

6. Condicionantes de acceso a nuevos medicamentos dermatológicos en España: Resultados del proyecto EQUIDAD

Author

Sánchez-Díaz, M., primary, Flórez, Á., additional, Ara-Martín, M., additional, Arias-Santiago, S., additional, Botella-Estrada, R., additional, Cañueto, J., additional, Carretero-Hernández, G., additional, Coto-Segura, P., additional, de Eusebio-Murillo, E., additional, García-Latasa de Araníbar, FJ., additional, García-Patos Briones, V., additional, Gardeazabal García, J., additional, Gómez-Fernández, C., additional, Hernández-Ostiz, S., additional, Izu Belloso, R., additional, López-Ávila, A., additional, Manchado López, P., additional, Martín-Santiago, A., additional, Martinez De Espronceda Ezquerro, I., additional, Mateu-Puchades, A., additional, Mercader-García, P., additional, Notario Rosa, J., additional, Palacio Aller, L., additional, Pérez-Hortet, C., additional, Quintana-Castanedo, L., additional, Rivera, R., additional, Rocamora Duran, V., additional, Rodríguez-Nevado, IM., additional, Ruiz-Villaverde, R., additional, Suárez, J., additional, Trasobares-Marugán, L., additional, Vizán-de Uña, C., additional, Yanguas, I., additional, Zulaica-Garate, A., additional, García-Doval, I., additional, Descalzo, MÁ., additional, Grau-Pérez, M., additional, and Carrascosa-Carrillo, JM., additional

Published
2023
Full Text
View/download PDF

9. BIOBADATOP: Registro Español de Dermatitis Atópica. Descripción y primeros resultados

Author

Munera-Campos, M., primary, Chicharro, P., additional, Gonzalez Quesada, A., additional, Florez Menendez, A., additional, de la Cueva Dovao, P., additional, Gimenez Arnau, AM., additional, Gilaberte Calzada, Y., additional, Rodríguez Serna, M., additional, Montero, T., additional, Silvestre Salvador, JF., additional, Elosua González, M., additional, del Alcazar, E., additional, Santamaría, C., additional, Sánchez-Pérez, J., additional, Carretero Hernández, G., additional, Batalla Cebey, A., additional, Jin Suh Oh, H., additional, Mauleón Fernández, C., additional, Curto Barredo, L., additional, Bertolín, M., additional, Navarro Bielsa, A., additional, Ballano Ruiz, A., additional, Botella Estrada, R., additional, Arias Santiago, S., additional, Betlloch, I., additional, Roustan Gullón, G., additional, Rosell Díaz, A., additional, Descalzo, MÁ., additional, García-Doval, I., additional, and Carrascosa, JM., additional

Published
2023
Full Text
View/download PDF

10. [Translated article] Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer – Basal Cell Carcinoma or Squamous Cell Carcinoma – Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study

Author

Minano Medrano, R, Lopez Estebaranz, J L, Sanmartin-Jimenez, O, Garces, J R, Rodriguez-Prieto, M A, Vilarrasa-Rull, E, de Eusebio-Murillo, E, Escutia-Munoz, B, Florez-Menendez, A, Artola-Igarza, J L, Alfaro-Rubio, A, Redondo, P, Delgado-Jimenez, Y, Sanchez-Schmidt, J M, Allende-Markixana, I, Alonso-Pacheco, M L, Garcia-Bracamonte, B, de la Cueva-Dobao, P, Navarro-Tejedor, R, Ciudad-Blanco, C, Carnero-Gonzalez, L, Vazquez-Veiga, H, Cano-Martinez, N, Ruiz-Salas, V, Sanchez-Sambucety, P, Botella-Estrada, R, Gonzalez-Sixto, B, Martorell-Calatayud, A, Gil, P, Morales-Gordillo, V, Toll-Abello, A, Ocerin-Guerra, I, Mayor-Arenal, M, Suarez-Fernandez, R, Sainz-Gaspar, L, Descalzo, M A, and Garcia-Doval, I

Subjects
Carcinoma epidermoide cutáneo, Incidence, Carcinoma basocelular, General Medicine, Segunda neoplasia, Risk factors, Second cancer, Squamous cell carcinoma, Basal cell carcinoma, Cirugía micrográfica de Mohs, Incidencia, Mohs micrographic surgery, Factores de riesgo
Abstract

OBJECTIVE: Patients with nonmelanoma skin cancer (NMSC)-ie, basal cell carcinoma (BCC) or squamous cell carcinoma (SCC)-have an increased risk of developing a second skin cancer. The aim of this study was to describe the frequency, incidence per 1000 person-years, and predictors of a second skin cancer in a cohort of patients with NMSC treated with Mohs micrographic surgery (MMS). MATERIAL AND METHODS: Prospective study of a national cohort of patients with NMSC who underwent MMS at 22 Spanish hospitals between July 2013 and February 2020; case data were recorded in the REGESMOHS registry. The study variables included demographic characteristics, frequency and incidence per 1000 person-years of second skin cancers diagnosed during the study period, and risk factors identified using mixed-effects logistic regression. RESULTS: We analyzed data for 4768 patients who underwent MMS; 4397 (92%) had BCC and 371 (8%) had SCC. Mean follow-up was 2.4 years. Overall, 1201 patients (25%) developed a second skin cancer during follow-up; 1013 of the tumors were BCCs (21%), 154 were SCCs (3%), and 20 were melanomas (0.4%). The incidence was 107 per 1000 person-years (95% CI, 101-113) for any cancer, 90 per 1000 person-years (95% CI, 85-96) for BCC, 14 (95% CI, 12-16) per 1000 person-years for SCC, and 2 (95% CI, 1-3) per 1000 person-years for melanoma. More men than women developed a subsequent skin cancer (738 [61%] vs 463 [39%]). The main risk factors were a history of multiple tumors before diagnosis (relative risk [RR], 4.6; 95% CI, 2.9-7.1), immunosuppression (RR, 2.1; 95% CI, 1.4-3.1), and male sex (RR, 1.6; 95% CI, 1.4-1.9). CONCLUSION: Patients have an increased risk of developing a second tumor after MMS treatment of NMSC. Risk factors are a history of multiple tumors at diagnosis, immunosuppression, and male sex.

Published
2022
Full Text
View/download PDF

11. [Translated article] Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience

Author

Nieto Benito, L M, Carretero, G, Rivera-Diaz, R, Carrascosa, J M, Dauden, E, de la Cueva, P, Sahuquillo-Torralba, A, Herrera-Acosta, E, Baniandres-Rodriguez, O, Lopez-Estebaranz, J L, Belinchon, I, Riera-Monroig, J, Ferran, M, Gomez-Garcia, F J, Mateu, A, Rodriguez, L, Vilar-Alejo, J, Garcia-Donoso, C, Ballesca, F, Velasco, L-M, Botella-Estrada, R, Herrera-Ceballos, E, Ruiz-Genao, D P, Descalzo, M A, and Garcia-Doval, I

Subjects
Psoriasis, Registros, Registries, General Medicine, Infancia, BIOBADADERM, Childhood
Abstract

Childhood-onset psoriasis generally follows an indolent course but patients with moderate or severe disease may require systemic treatment. The aim of this study was to determine the relative proportion of children and young people aged up to 21 years with moderate to severe psoriasis in the BIOBADADERM registry and to analyze the characteristics of these patients, treatments used, and adverse events. Of the 3946 patients in the registry, 24 were aged 21 years or younger. The mean age of this group when they started treatment upon registration on Biobadaderm was 16.1 years and the mean Psoriasis Area and Severity Index was 9.4. In 67% the first treatment recorded was with a conventional systemic drug. Treatment was discontinued in 14 patients (58%) due to adverse events or a loss or lack of effectiveness. In conclusion, the BIOBADADERM registry shows that young people account for a small proportion of psoriasis patients receiving systemic treatment, and they are more likely to be treated using conventional systemic drugs.

Published
2022
Full Text
View/download PDF

12. Condicionantes de acceso a nuevos medicamentos dermatológicos en España: resultados del proyecto EQUIDAD

Author

Sánchez-Díaz, M., Flórez, Á., Ara-Martín, M., Arias-Santiago, S., Botella-Estrada, R., Cañueto, J., Carretero-Hernández, G., Coto-Segura, P., de Eusebio-Murillo, E., García-Latasa de Araníbar, F.J., García-Patos Briones, V., Gardeazabal García, J., Gómez-Fernández, C., Hernández-Ostiz, S., Izu Belloso, R., López-Ávila, A., Manchado López, P., Martín-Santiago, A., Martinez de Espronceda Ezquerro, I., Mateu-Puchades, A., Mercader-García, P., Notario Rosa, J., Palacio Aller, L., Pérez-Hortet, C., Quintana-Castanedo, L., Rivera, R., Rocamora Duran, V., Rodríguez-Nevado, I.M., Ruiz-Villaverde, R., Suárez, J., Trasobares-Marugán, L., Vizán-de Uña, C., Yanguas, I., Zulaica-Garate, A., García-Doval, I., Descalzo, M.Á., Grau-Pérez, M., and Carrascosa-Carrillo, J.M.

Abstract

[Display omitted]

Published
2024
Full Text
View/download PDF

13. Registro de linfomas cutáneos primarios (RELCP) de la AEDV: datos tras 5 años de funcionamiento

Author

Falkenhain-López, D., primary, Muniesa, C., additional, Estrach, M.T., additional, Morillo-Andújar, M., additional, Peñate, Y., additional, Acebo, E., additional, Pujol, R.M., additional, García-Muret, M.P., additional, Machan, S., additional, Medina, S., additional, Botella-Estrada, R., additional, Fernández de Misa, R., additional, Blanes, M., additional, Flórez, A., additional, Pérez-Paredes, G., additional, Izu, R., additional, Yanguas, I., additional, Silva-Díaz, E., additional, Pérez-Ferriols, A., additional, Prieto-Torres, L., additional, Zayas, A., additional, Parera-Amer, M.E., additional, Pérez, A., additional, Aspe, L., additional, Román, C., additional, Sánchez-Caminero, M.P., additional, Bassas-Vila, J., additional, Domínguez-Auñón, J.D., additional, Calzado, L., additional, Navedo, M., additional, Ortiz-Prieto, A., additional, Servitje, O., additional, Polo-Rodríguez, I., additional, Torres, I., additional, Hernández-Hernández, M.N., additional, Mitxelena-Eceiza, J., additional, García-Vázquez, A., additional, García-Doval, I., additional, and Ortiz-Romero, P.L., additional

Published
2022
Full Text
View/download PDF

14. Riesgo de aparición de segundas neoplasias cutáneas en una cohorte de pacientes diagnosticados de carcinoma queratinocítico (carcinoma basocelular y carcinoma epidermoide) tratados con cirugía de Mohs. Estudio de cohortes prospectivo nacional

Author

Miñano Medrano, R., primary, López Estebaranz, J.L., additional, Sanmartin-Jiménez, O., additional, Garcés, J.R., additional, Rodríguez-Prieto, M.A., additional, Vilarrasa-Rull, E., additional, de Eusebio-Murillo, E., additional, Escutia-Muñoz, B., additional, Flórez-Menéndez, Á., additional, Artola-Igarza, J.L., additional, Alfaro-Rubio, A., additional, Redondo, P., additional, Delgado-Jiménez, Y., additional, Sánchez-Schmidt, J.M., additional, Allende-Markixana, I., additional, Alonso-Pacheco, M.L., additional, García-Bracamonte, B., additional, de la Cueva-Dobao, P., additional, Navarro-Tejedor, R., additional, Ciudad-Blanco, C., additional, Carnero-González, L., additional, Vázquez-Veiga, H., additional, Cano-Martínez, N., additional, Ruiz-Salas, V., additional, Sánchez-Sambucety, P., additional, Botella-Estrada, R., additional, González-Sixto, B., additional, Martorell-Calatayud, A., additional, Gil, P., additional, Morales-Gordillo, V., additional, Toll-Abelló, A., additional, Ocerin-Guerra, I., additional, Mayor-Arenal, M., additional, Suárez-Fernández, R., additional, Sainz-Gaspar, L., additional, Descalzo, M.A., additional, and García-Doval, I., additional

Published
2022
Full Text
View/download PDF

15. Psoriasis moderada-grave en pacientes pediátricos y jóvenes: experiencia en el registro BIOBADADERM

Author

Nieto Benito, LM, primary, Carretero, G, additional, Rivera-Díaz, R, additional, Carrascosa, JM, additional, Daudén, E, additional, de la Cueva, P, additional, Sahuquillo-Torralba, A, additional, Herrera-Acosta, E, additional, Baniandrés-Rodríguez, O, additional, Lopez-Estebaranz, JL, additional, Belinchón, I, additional, Riera-Monroig, J, additional, Ferrán, M, additional, Gómez-García, FJ, additional, Mateu, A, additional, Rodríguez, L, additional, Vilar-Alejo, J, additional, García-Donoso, C, additional, Ballescá, F, additional, Llamas-Velasco, M, additional, Botella-Estrada, R, additional, Herrera-Ceballos, E, additional, Ruiz-Genao, DP, additional, Descalzo, MA, additional, and García-Doval, I, additional

Published
2022
Full Text
View/download PDF

16. Psoriasis moderada-grave en pacientes pediátricos y jóvenes: experiencia en el registro BIOBADADERM

Author

Nieto Benito, LM, primary, Carretero, G, additional, Rivera-Díaz, R, additional, Carrascosa, JM, additional, Daudén, E, additional, de la Cueva, P, additional, Sahuquillo-Torralba, A, additional, Herrera-Acosta, E, additional, Baniandrés-Rodríguez, O, additional, Lopez-Estebaranz, JL, additional, Belinchón, I, additional, Riera-Monroig, J, additional, Ferrán, M, additional, Gómez-García, FJ, additional, Mateu, A, additional, Rodríguez, L, additional, Vilar-Alejo, J, additional, García-Donoso, C, additional, Ballescá, F, additional, Llamas-Velasco, M, additional, Botella-Estrada, R, additional, Herrera-Ceballos, E, additional, Ruiz-Genao, DP, additional, Descalzo, MA, additional, and García-Doval, I, additional

Published
2021
Full Text
View/download PDF

18. Guía de práctica clínica de melanoma de la Academia Española de Dermatología y Venereología

Author

Botella-Estrada, R., primary, Boada-García, A., additional, Carrera-Álvarez, C., additional, Fernández-Figueras, M., additional, González-Cao, M., additional, Moreno-Ramírez, D., additional, Nagore, E., additional, Ríos-Buceta, L., additional, Rodríguez-Peralto, J.L., additional, Samaniego-González, E., additional, Tejera-Vaquerizo, A., additional, Vílchez-Márquez, F., additional, Descalzo-Gallego, M.A., additional, and García-Doval, I., additional

Published
2021
Full Text
View/download PDF

19. Cambios en las tendencias de la prescripción y causas de la interrupción en los tratamientos biológicos indicados en la psoriasis durante los primeros 10 años. Datos obtenidos del registro español Biobadaderm

Author

Ruiz-Genao, D.P., primary, Carretero, G., additional, Rivera, R., additional, Ferrándiz, C., additional, Daudén, E., additional, de la Cueva, P., additional, Belinchón, I., additional, Gómez-García, F.J., additional, Herrera-Acosta, E., additional, López-Estebaranz, J.L., additional, Ferrán-Farrés, M., additional, Alsina, M., additional, Baniandrés-Rodríguez, O., additional, Sánchez-Carazo, J.L., additional, Sahuquillo-Torralba, A., additional, Rodriguez, L., additional, Vilar-Alejo, J., additional, García-Donoso, C., additional, Carrascosa, J.M., additional, Llamas-Velasco, M., additional, Herrera-Ceballos, E., additional, Botella-Estrada, R., additional, Descalzo, M.A., additional, and García-Doval, I., additional

Published
2020
Full Text
View/download PDF

22. Telomerase Expression in a Series of Melanocytic Neoplasms

Author

Moles Poveda P, Llavador Ros M, Palanca Suela S, Botella Estrada R, Sahuquillo Torralba A, Simarro Farinos J, De Unamuno Bustos B, and Pérez Simó G

Subjects
0301 basic medicine, Senescence, Adult, Male, Telomerase, Histology, Skin Neoplasms, Dermatology, Pathology and Forensic Medicine, Breslow Thickness, 03 medical and health sciences, 0302 clinical medicine, medicine, Nevus, Humans, Telomerase reverse transcriptase, neoplasms, Melanoma, Aged, Retrospective Studies, Nevus, Pigmented, business.industry, Middle Aged, medicine.disease, Telomere, 030104 developmental biology, 030220 oncology & carcinogenesis, Cancer research, Immunohistochemistry, Female, business
Abstract

Background and objectives Telomerase is an enzyme involved in maintaining the length of telomeres and cell senescence. Numerous studies have shown that in more than 90% of malignant tumors telomerase activity is detected. Material and methods Retrospective observational study in a series of 85 cases of primary melanomas, 12 metastatic melanomas, and 22 melanocytic nevi. We used the monoclonal antibody hTERT (human telomerase reverse transcriptase, Rockland) to assess telomerase activity. The SPSS software package was used to analyze data. Results Telomerase expression was present in all the melanocytic neoplasms analyzed. Expression was heterogenous and moderate or high in the melanomas. In contrast, expression was homogeneous and lower in the nevi. Heterogeneous expression was associated with rapid melanoma growth (P = .028), a Breslow thickness of more than 4 mm (P = .004), mitosis (P = .032), and mutations in the TERT gene (P = .002). Activity was less intense in intradermal nevi, and more intense in compound and dysplastic nevi (P = .054). Conclusions Telomerase expression is found in all melanocytic neoplasms but is higher in melanomas than in nevi. A heterogeneous pattern of expression in melanomas is associated with more aggressive tumors.

Published
2018

29. Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma

Author

San Martín, O., Llombart, B., Carretero Hernandez, G., Flórez Menéndez, Á., Botella-Estrada, R., Herrera Ceballos, E., and Puig, S.

Abstract

Sonidegib is an antagonist of the transmembrane protein Smoothened in the Hedgehog signaling pathway. It is indicated for the treatment of locally advanced basal cell carcinoma (BCC) that is not amenable to curative surgery or radiotherapy. Sonidegib’s efficacy and safety were demonstrated in the phase 2 BOLT trial, where 61% (95% CI, 48%–72%) of patients with locally advanced BCC treated with sonidegib 200 mg achieved an objective response to treatment with a mean time to response of 4 months. The median duration of response was 26.1 months and the median progression-free survival was 22.1 months. The most common adverse events were muscle spasms (54.4%), hair loss (49.4%), and loss of taste (44.3%); most events were grade 1 or 2. In this review, we summarize the main findings on the efficacy, safety, and tolerability of sonidegib and discuss the management of locally advanced BCC with this drug.

Published
2021
Full Text
View/download PDF

30. Clinical Practice Guideline on Melanoma From the Spanish Academy of Dermatology and Venereology (AEDV)

Author

Botella-Estrada, R., Boada-García, A., Carrera-Álvarez, C., Fernández-Figueras, M., González-Cao, M., Moreno-Ramírez, D., Nagore, E., Ríos-Buceta, L., Rodríguez-Peralto, J.L., Samaniego-González, E., Tejera-Vaquerizo, A., Vílchez-Márquez, F., Descalzo-Gallego, M.A., and García-Doval, I.

Abstract

Specialist approaches to the diagnosis and treatment of melanoma have undergone many changes. This guideline aims to provide Spanish dermatologists with evidence-based information for resolving the most common doubts that arise in clinical practice. Members of the Spanish Oncologic Dermatology and Surgery Group (GEDOC) with experience treating melanoma were invited to participate in drafting the guideline. The group developed a new guideline on the basis of existing ones, using the ADAPTE collaboration process, first summarizing the care process and posing relevant clinical questions, then selecting guidelines with the best scores according to the AGREE II (Appraisal of Guidelines for Research and Evaluation) tool. Finally, the group searched the selected guidelines for answers to the clinical questions, drafted recommendations, and sent them for external review. The guideline is structured around 21 clinical questions chosen for their relevance to issues that make clinical decisions about the management of melanoma difficult. Evidence from existing guidelines was used to answer the questions. A limitation of this guide derives from the scarce evidence available for answering some questions. Moreover, some areas are changing rapidly, so recommendations must be updated often. The present guideline offers answers to clinical questions about the routine management of melanoma in clinical practice and provides dermatologists with a reference to guide decisions, taking into consideration the resources available and patient preferences.

Published
2021
Full Text
View/download PDF

34. Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry

Author

Ruiz-Genao, D.P., Carretero, G., Rivera, R., Ferrándiz, C., Daudén, E., de la Cuev, P., Belinchón, I., Gómez-García, F.J., Herrera-Acosta, E., López-Estebaranz, J.L., Ferrán-Farrés, M., Alsina, M., Baniandrés-Rodríguez, O., Sánchez-Carazo, J.L., Sahuquillo-Torralba, A., Rodriguez, L., Vilar-Alejo, J., García-Donoso, C., Carrascosa, J.M., Llamas-Velasco, M., Herrera-Ceballos, E., Botella-Estrada, R., Descalzo, M.A., and García-Doval, I.

Abstract

Current psoriasis guidelines do not usually include recommendations about first line classical or biologic treatment. The objectives of this study were: to describe shifts in the prescription of the first biological treatment, and to compare treatment withdrawal and rates of adverse events over ten years.

Published
2020
Full Text
View/download PDF

36. A review of terms used to define cutaneous squamous cell carcinoma with a poor prognosis

Author

Cañueto, J., Tejera-Vaquerizo, A., Redondo, P., Botella-Estrada, R., Puig, S., and Sanmartin, O.

Abstract

Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer in humans and its incidence is both underestimated and on the rise. cSCC is referred to in the literature as high-risk cSCC, locally advanced cSCC, metastatic cSCC, advanced cSCC, and aggressive cSCC. These terms can give rise to confusion and are not always well defined. In this review, we aim to clarify the concepts underlying these terms with a view to standardizing the description of this tumor, something we believe is necessary in light of the new drugs that have been approved or are in development for cSCC.

Published
2020
Full Text
View/download PDF

37. Perfil clínico, epidemiológico y respuesta al tratamiento, en función de la comorbilidad atópica asociada en la dermatitis atópica. Experiencia del registro BIOBADATOP

Author

Peris-Espino, V., Munera-Campos, M., Chicharro, P., Gonzalez Quesada, A., Florez Menendez, A., de la Cueva Dobao, P, Gimenez Arnau, AM., Gilaberte Calzada, Y., Rodriguez Serna, M., Montero-Vilchez, T., Silvestre Salvador, J.F., Ruiz-Villaverde, R., Elosua-Gonzalez, M., Del Alcázar-Viladomiu, E., Sánchez-Pérez, J., Carretero Hernández, G., Batalla, A., Suh Oh, H.J., Couselo-Rodríguez, C., Mauleón Fernández, C., Curto-Barredo, L., Bertolín-Colilla, M., Navarro-Bielsa, A., Ballano Ruiz, A., Botella Estrada, R., Arias-Santiago, S., Sanabria-de-la-Torre, R., Betlloch-Mas, I., Navarro-Triviño, F.J., Roustan Gullón, G., Rosell-Díaz, A., Loro-Pérez, M., Suárez-Perez, J., García-Doval, I., Descalzo-Gallego, M.Á., and Carrascosa Carrillo, J.M.

Abstract

Antecedentes: Pese al avance terapéutico en la dermatitis atópica (DA), la información sobre el impacto y la interacción con las comorbilidades atópicas (como el asma, la rinoconjuntivitis y la patología ocular) es limitada. Este estudio pretende evaluar las características clínicas y epidemiológicas de pacientes con DA, así como la respuesta al tratamiento, considerando dichas comorbilidades.

Published
2024
Full Text
View/download PDF

43. Análisis multicéntrico del manejo quirúrgico y tratamiento adyuvante de los pacientes con melanoma y positividad en la biopsia selectiva del ganglio centinela

Author

Samaniego-González, E., Podlipnik, S., Ribero, S., Nagore, E., Boada, A., Cañueto, J., Paradela, S., de Unamuno, B., Rodríguez-Jiménez, P., Puig, S., Malvehy, J., Carrera, C., Roccuzzo, G., Requena, C., Manrique-Silva, E., Richarz, N., Ruiz-Villanueva, A., Traves, V., España-Fernández, S., Botella-Estrada, R., González-Morán, M.A., and Tejera-Vaquerizo, A.

Abstract

La disección ganglionar completa (DGC) era la práctica estándar en pacientes con melanoma y biopsia selectiva del ganglio centinela (BSGC) positiva hasta que, en 2016 y 2017 se publicaron los resultados de dos ensayos clínicos que no demostraron que mejorase la supervivencia específica por melanoma (SEM). Sin embargo, continúa realizándose en algunos escenarios. No existen estudios que recojan el manejo ganglionar tras BSGC positivo en la práctica clínica en nuestro medio.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results